Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1990667 | 0.98 | OPRM1 (0.56) | OPRM1HDAC1AKR1C1TACR1OPRL1 | |
| Trifluoroacetic Acid SCHEMBL16413809 | 0.91 | OPRM1 (0.50) | OPRM1HDAC1AKR1C1TACR1OPRL1 | |
| SCHEMBL6632931 | 0.87 | SIGMAR1 (0.56) | OPRM1HDAC1TACR1OPRL1HSD11B1 | |
| SCHEMBL2722547 | 0.86 | AKR1C1 (0.57) | OPRM1HDAC1AKR1C1OPRL1HSD11B1 | |
| SCHEMBL501923 | 0.86 | AKR1C1 (0.57) | OPRM1HDAC1AKR1C1OPRL1HSD11B1 | |
| SCHEMBL373567 | 0.85 | AKR1C1 (0.68) | OPRM1HDAC1AKR1C1TACR1HTR2A | |
| Hydrochloric Acid SCHEMBL1804765 | 0.84 | AKR1C1 (0.55) | OPRM1HDAC1AKR1C1OPRL1HSD11B1 | |
| SCHEMBL4219088 | 0.84 | OPRM1 (0.42) | OPRM1HDAC1HSD11B1 | |
| Ammonia Solution, Strong SCHEMBL3210975 | 0.83 | AKR1C1 (0.66) | OPRM1HDAC1AKR1C1TACR1HTR2A | |
| Hydrochloric Acid SCHEMBL18281540 | 0.83 | AKR1C1 (0.66) | OPRM1HDAC1AKR1C1TACR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3914246-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | ICM (Institut du Cerveau et de la Moelle Épinière) (FR) | 2021-12-01 | — | — | EP | claimed |
| WO-2020152212-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2020-07-30 | — | — | WO | claimed |
| WO-2014146082-A1 | MATERIALS AND METHODS FOR TREATING NEUROPATHIES AND RELATED DISORDERS INCLUDING THOSE INVOLVING A KEYSTONE NERVE | BHL PATENT HOLDINGS LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-7417027-B2 | Linear and cyclic melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2008-08-26 | — | — | US | claimed |
| EP-1834627-A1 | Skin conditioning compositions and methods of use thereof | JR Chemicals (US) | 2007-09-19 | — | — | EP | claimed |
| US-20070190190-A1 | Conditioning compositions and methods of use thereof | JR CHEM, LLC | 2007-08-16 | — | — | US | claimed |
| EP-1813295-A2 | Coated surgical needles | TYCO HEALTHCARE GROUP LP (US) | 2007-08-01 | — | — | EP | claimed |
| EP-1441750-A4 | LINEAR AND CYCLIC MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2006-10-18 | — | — | EP | claimed |
| US-20060190040-A1 | Coated surgical needles | TYCO HEALTHCARE GROUP, LP | 2006-08-24 | — | — | US | claimed |
| US-20050038230-A1 | Linear and cyclic melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2005-02-17 | — | — | US | claimed |
| EP-1441750-A2 | LINEAR AND CYCLIC MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | Palatin Technologies, Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| EP-0999839-B1 | COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES | LEVIN BRUCE H (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2003006620-A2 | LINEAR AND CYCLIC MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-6432986-B2 | INTRANOSALLY ADMINISTERING OF ANESTHETICS | BHL PATENT HOLDINGS LLC | 2002-08-13 | — | — | US | claimed |
| US-20010055607-A1 | COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES | BHL PATENT HOLDINGS LLC | 2001-12-27 | — | — | US | claimed |
| WO-2001043733-A2 | COMPOSITIONS, KITS, APPARATUS, AND METHODS FOR INHIBITING CEPHALIC INFLAMMATION | LEVIN BRUCE H (US) | 2001-06-21 | — | — | WO | claimed |
| US-20010004644-A1 | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation | LEVIN BRUCE H (US) | 2001-06-21 | — | — | US | claimed |
| CN-122036731-A | CB1 receptor inverse agonist compound, pharmaceutical composition, preparation method and application thereof | 北京康辰药业股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-4369184-A | ANTIHISTAMINES; HETEROCYCLIC NITRILES | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-18 | — | — | US | disclosed |
| EP-0034415-A1 | 1-(Cyclohexyl or cyclohexenyl)-4-aryl-4-piperidinecarboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010055607-A1 | COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES | TNNC1, KIT, PDE3A | OPRM1 1213/4885HDAC1 1305/4885AKR1C1 1320/4885 |
| US-20010004644-A1 | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation | CXCR5, CCL5, C5AR2 | OPRM1 320/4885HDAC1 1405/4885AKR1C1 1350/4885 |
| US-20050038230-A1 | Linear and cyclic melanocortin receptor-specific peptides | MC1R, MC3R, MC5R | OPRM1 94/4885HDAC1 3896/4885AKR1C1 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.